Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02927262
Status:
COMPLETED
Last Update Posted:
2024-03-15
First Post:
2016-10-05
Brief Title:
A Study of ASP2215 Gilteritinib Administered as Maintenance Therapy Following InductionConsolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 FLT3ITD Acute Myeloid Leukemia AML in First Complete Remission
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-01-10
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-19
Completion Date Type:
ACTUAL
First Submit Date:
2016-10-05
First Submit QC Date:
October 5 2016
Study First Post Date:
2016-10-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-06-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-13
Last Update Post Date:
2024-03-15
Last Update Post Date Type:
ACTUAL